Children with Sanfilippo syndrome type A lose skills they have already gained, develop seizures, and die young. The cause is unambiguous: a single gene variant blocks the production of an enzyme called sulfamidase, and without it, cellular waste accumulates.
Alzheimer's disease is nothing like that. It arrives late, its causes are contested, and decades of research have centered on amyloid plaques accumulating outside brain cells.
Researchers at UC San Diego now report that the two diseases converge on the same cellular failure inside the brain's immune cells. The work was published in Immunity and announced Aug. 11.
Microglia Bear the Brunt
Lysosomes are the compartments where cells break down nutrients, destroy invaders and recycle worn-out parts. In Sanfilippo syndrome type A (MPS IIIA), the missing enzyme causes the machinery to jam and debris to accumulate.
Studying a mouse model of the disease, the team found that waste built up across many cell types but that microglia, the brain's dedicated immune cells, were affected most severely. Images from the study show healthy microglia beside microglia so clogged with fats and proteins that they have visibly swollen.
Bloated microglia stop doing their job. As they expand, they lose the ability to protect neurons.
That is a meaningful loss. Microglia are the brain's resident cleanup and defense system, clearing debris, pruning connections, and responding to injury. A brain whose immune cells are themselves choked with waste has lost the very thing that would normally manage it.
A Switch That Flips from Protective to Destructive
The mechanism the researchers identified is a family of proteins called MITF/TFE, which act as master genetic switches.
When lysosomes in microglia become overburdened and stressed, those switches flip from off to on, triggering a sweeping change in the cell's genetic program. The initial purpose appears protective. Over time, it becomes maladaptive, fueling inflammation and contributing to neuronal death.
The surprise came when the team examined human Alzheimer's brain tissue. The same MITF/TFE switches were turned on in microglia there, in response to waste accumulation.
That similarity is what gives a rare pediatric disease unexpected leverage over a common one. MPS IIIA has a clear-cut single-gene cause. Alzheimer's does not, which is why the mechanisms driving it remain so hard to isolate.
"It gave us a really clear framework to study what we see in common neurodegenerative diseases and try to figure out mechanisms that are causing them," said first author Christopher Balak, a postdoctoral researcher in the laboratory of corresponding author Christopher Glass at UC San Diego School of Medicine.
Damage from the Inside Rather Than the Outside
The finding pushes against a widely held assumption in Alzheimer's research.
Many researchers hold that amyloid plaques sitting outside microglia cause lysosomes to fail from the outside in. Balak argues the damage can originate inside the cell instead.
"We know lysosomes alone are sufficient to cause neurodegeneration from rare disorders like MPS IIIA," he said, adding that the same process could be contributing to Alzheimer's.
The distinction is not academic, because it points to a different drug target. Most microglia-targeted drugs go after receptors on the cell surface. Balak suggests that the lysosomal program within the cell may be a more useful handle.
The team also found that microglia try to limit damage early in the disease process, before they are overwhelmed. That timing, if it holds up, would argue for intervening with enzyme replacement or cell therapies before the switch flips. For Sanfilippo syndrome, where the enzyme deficiency is known and replacement approaches are already under investigation, that is actionable framing. For Alzheimer's, where the equivalent early window is far less well defined, it is a hypothesis about timing rather than a treatment plan. The full announcement is available from UC San Diego.
Where the Evidence Runs Out
The mouse model establishes a mechanism. The human component is observational: the same switches were found to be turned on in microglia from Alzheimer's patients. That is a shared signature, not proof that the two diseases share a cause or would respond to the same treatment.
No drug targeting MITF/TFE exists. Nothing in this work changes Alzheimer's diagnosis or care, and it is not evidence that treatments for one disease will work for the other. An earlier preprint from the group laid out the imaging, transcriptomic, and epigenetic groundwork in the mouse model.
The scale of the problem it speaks to is large. An estimated 7.4 million Americans aged 65 and older are living with clinical Alzheimer's dementia, and care costs are projected to reach $409 billion this year, according to the Alzheimer's Association.
Glass is a co-founder and scientific advisory board member of Asteroid 633 Therapeutics. The work was funded in part by the National Institutes of Health and the National Science Foundation, with co-authors at the Broad Institute of MIT and Harvard, Boston Children's Hospital, Harvard Medical School, the University of Utah, the University of Miami, and Ionis Pharmaceuticals.
People with questions about their own or a family member's cognitive symptoms should speak with a clinician.
Key Questions Answered
What did the study find?
That lysosomal failure in microglia triggers a genetic switch, the MITF/TFE protein family, that is active in both Sanfilippo syndrome type A and Alzheimer's disease.
What is Sanfilippo syndrome type A?
A rare childhood disorder, also called MPS IIIA, is caused by a gene variant blocking the production of the enzyme sulfamidase. It causes seizures and dementia and leads to early death.
Why compare a rare disease to Alzheimer's?
Because MPS IIIA has a single clear cause, it offers a simplified framework for studying processes that are tangled in Alzheimer's.
Does this mean the diseases are the same?
No. The study identifies a shared cellular signature, not a shared cause or a shared treatment.
What is the potential drug angle?
Targeting the lysosomal program inside microglia rather than receptors on the cell surface, which is where most current microglia drugs act.
Was this done in humans?
Partly. The mechanistic work used a mouse model. The Alzheimer's comparison used human patient microglia.
Are there disclosures?
Yes. The corresponding author is a co-founder and scientific advisory board member of Asteroid 633 Therapeutics.
